TATAINVEST Q1 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹145 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Tata Elxsi reported Q1 FY26 operating revenue of INR 892.1 crore with EBITDA margin of 20.9%, reflecting significant margin compression from historical levels of 25%+ due to revenue decline and transition investments in large media consolidation deals. Transportation business (50%+ of revenues) was flat in constant currency, with deal ramp-ups proceeding as planned for Mercedes-Benz and Suzuki, while OEM mix improved to 72-75% of transportation revenues. Media & communications declined 5.5% QoQ due to rate reset on large consolidation deal and transition costs; management expects recovery in Q2. Healthcare declined 6.7% QoQ impacted by US customer project pauses; recovery targeted for H2. Management guides margin improvement over next three quarters as revenues normalize, with medium-term aspiration of 29-30% EBITDA margins. Aerospace & defense vertical is being built with ~150 people team, targeting INR 50 crore revenue this year. Talent additions of 400+ fresh engineers planned. Key risks include tier-1 automotive weakness, US OEM uncertainty, and tariff-related healthcare volatility.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects gradual margin improvement over the next three quarters as transportation and media businesses return to growth and utilization improves.
- Media & communications expected to return to growth in Q2 FY26 on back of deal ramp-ups from large consolidation wins and healthy deal pipeline.
- Healthcare vertical expected to see recovery in H2 FY26 with ramp-up of new logos (European pharma/biotech leader, Japanese medtech leader) and paused US projects restarting in Q2.
- Targeting INR 50 crore revenue this year from aerospace & defense vertical; medium-term goal to ramp up significant business over 2-3 years.
Risks flagged
- Tier-1 suppliers continue to be stressed as OEMs take more ownership of software and tier-1s operate from their own GCCs. Revenue from tier-1s may continue declining.
- Tariff-related uncertainty affecting US medical devices customers with project pauses; smaller customer base makes this vertical more volatile. Recovery dependent on new logo ramp-ups.
- US market remains slow with some OEM customers experiencing project stoppages and lack of clarity on restart timing for discussions.
- Large consolidation deal in media reset portfolio rates lower; while a 3-year commitment exists, revenue impact from rate reset already reflected in Q1.
Key quotes
- The confidence is because we had certain ramp-ups to happen in Q1. I'm happy to tell you that the Q1 ramp-up has happened as per expectation. We don't see any pullback. We don't see any slowdown that is happening from the ramp-up perspective.
- Unlike IT or a BPO or some other industries, the impact of AI is still not going to be very dramatic as we speak... You cannot assume that because AI and GenAI is now available, you will be able to deploy lesser manpower. For certain tasks, it is possible. For certain types of projects, it is possible. It is not a generic solution for all projects.
- We have reached the bottom from Tata Elxsi's perspective... Hopefully, from the coming quarter, we should be able to report better results in this particular vertical.
Research modules